News

Archive

Ventyx Biosciences announces key appointments and closing of $51m Series B financing VORAGO Technologies announces low-cost and immediately available rad-tolerant hi-rel MCU for New Space, LEO market Isorg raises €16 million in Series C financing Bioasis Technologies Inc and Oxyrane UK Ltd enter into a Research Collaboration Resolve Therapeutics receives FDA approval to initiate Phase 2 clinical trial of RSLV-132 in long covid patients Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.